Literature DB >> 7888013

RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism.

D R Garrel1, R Moussali, A De Oliveira, D Lesiège, F Larivière.   

Abstract

Glucocorticoids have deleterious effects on glucose and protein metabolism. RU 486 is an antiprogestin with antiglucocorticoid activity, which could be used to prevent the undesirable metabolic effects of glucocorticoids. A randomized, controlled, double blind study was performed in eight healthy male volunteers who were tested four times: during the iv infusion of cortisol (2 micrograms/kg.min for 5 h) after the oral ingestion of RU 486 (600 mg) or a placebo, and during the infusion of a normal saline solution with placebo or RU 486 ingestion. During each test, a primed continuous iv infusion of D-[6,6-2H]glucose and [1-13C-]leucine was given for the calculation of hepatic glucose production and plasma leucine appearance rate. 13CO2 enrichment in breath was measured for the calculation of leucine oxidation. Plasma concentrations of cortisol, ACTH, insulin, C-peptide, glucagon, and GH were measured at regular intervals. Compared to saline, cortisol infusion increased plasma glucose 5.5 +/- 0.6 vs. 4.7 +/- 0.4 mmol/L; P < 0.01) and leucine (179 +/- 35 vs. 155 +/- 35 mumol/L; P < 0.01) concentrations as well as the leucine appearance rate (2.24 +/- 0.3 vs. 2.0 +/- 0.28 mumol/kg.min; P < 0.05) and oxidation (0.51 +/- 0.22 vs. 0.39 +/- 0.06 mumol/kg.min; P < 0.01), and there was no change in hepatic glucose production. None of the metabolic changes induced by cortisol were seen when cortisol was administered after the ingestion of RU 486. When RU 486 was given before normal saline infusion, plasma glucose concentrations were transiently lower than those after placebo ingestion, as was the hepatic glucose production. No change in insulin, C-peptide, or glucagon was seen between tests. GH concentrations were higher during cortisol infusion, but not when cortisol was administered after the ingestion of RU 486. The following conclusions were reached. 1) RU 486 can suppress the effects of acute hypercortisolemia on glucose and protein metabolism and GH secretion in man. Long term studies are warranted to explore the potential of antiglucocorticoid molecules as preventive agents of the deleterious effects of chronic glucocorticoid administration. 2) RU 486 is useful molecule for studying the metabolic effects of cortisol in man.

Entities:  

Keywords:  Adrenal Cortex Hormones; Americas; Biology; Canada; Carbohydrate Metabolic Effects; Deficiency Diseases; Developed Countries; Diseases; Double-blind Studies; Endocrine System; Glucose Metabolism Effects; Hormone Antagonists; Hormones; Metabolic Effects; North America; Northern America; Nutrition Disorders; Physiology; Proteins; Research Report; Ru-486; Studies

Mesh:

Substances:

Year:  1995        PMID: 7888013     DOI: 10.1210/jcem.80.2.7888013

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Influence of Dexamethasone on O-(2-[18F]-Fluoroethyl)-L-Tyrosine Uptake in the Human Brain and Quantification of Tumor Uptake.

Authors:  Carina Stegmayr; Gabriele Stoffels; Elena Rota Kops; Philipp Lohmann; Norbert Galldiks; Nadim J Shah; Bernd Neumaier; Karl-Josef Langen
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

Review 2.  Gastroprotective action of glucocorticoid hormones during NSAID treatment.

Authors:  L P Filaretova; T T Podvigina; T R Bagaeva; A Tanaka; K Takeuchi
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

3.  Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone.

Authors:  Maria Fleseriu; James W Findling; Christian A Koch; Sven-Martin Schlaffer; Michael Buchfelder; Coleman Gross
Journal:  J Clin Endocrinol Metab       Date:  2014-07-11       Impact factor: 5.958

4.  Mifepristone Improves Adipose Tissue Insulin Sensitivity in Insulin Resistant Individuals.

Authors:  Sriram Gubbi; Ranganath Muniyappa; Susmeeta T Sharma; Shivraj Grewal; Raven McGlotten; Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2021-04-23       Impact factor: 5.958

5.  Effect of a LoBAG30 diet on protein metabolism in men with type 2 diabetes. A Randomized Controlled Trial.

Authors:  Frank Q Nuttall; Mary C Gannon
Journal:  Nutr Metab (Lond)       Date:  2012-05-20       Impact factor: 4.169

6.  The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome.

Authors:  Minghan Wang
Journal:  Nutr Metab (Lond)       Date:  2005-02-02       Impact factor: 4.169

7.  RU486 did not exacerbate cytokine release in mice challenged with LPS nor in db/db mice.

Authors:  Baichun Yang; Ryan P Trump; Ying Shen; Judi A McNulty; Lisa G Clifton; Stephen A Stimpson; Peiyuan Lin; Greg L Pahel
Journal:  BMC Pharmacol       Date:  2008-05-12

8.  TAZ inhibits glucocorticoid receptor and coordinates hepatic glucose homeostasis in normal physiological states.

Authors:  Simiao Xu; Yangyang Liu; Ruixiang Hu; Min Wang; Oliver Stöhr; Yibo Xiong; Liang Chen; Hong Kang; Lingyun Zheng; Songjie Cai; Li He; Cunchuan Wang; Kyle D Copps; Morris F White; Ji Miao
Journal:  Elife       Date:  2021-10-08       Impact factor: 8.140

9.  Assessing the metabolic effects of prednisolone in healthy volunteers using urine metabolic profiling.

Authors:  Sandrine Ellero-Simatos; Ewa Szymańska; Ton Rullmann; Wim Ha Dokter; Raymond Ramaker; Ruud Berger; Thijs Mp van Iersel; Age K Smilde; Thomas Hankemeier; Wynand Alkema
Journal:  Genome Med       Date:  2012-11-30       Impact factor: 11.117

10.  Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with Type 2 diabetes with and without fatty liver.

Authors:  D P Macfarlane; P J Raubenheimer; T Preston; C D Gray; M E Bastin; I Marshall; J P Iredale; R Andrew; B R Walker
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-08-07       Impact factor: 4.052

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.